A Multicenter, Eight-Week Treatment, Single-Step Titration, Open-Label Study Assessing the Percentage of Korean Dyslipidemic Patients Achieving LDL Cholesterol Target with Atorvastatin Starting Doses of 10 mg, 20 mg and 40 mg

Author： Lee Cheol   Baek Sang-Hong   Hong Taek-Jong   Choi Young-Jin   Kim Young-Jo   Ahn Tae-Hoon   Ihm Sang-Hyun   Bae Jang-Ho   Hong Soon-Jun   Kim Doo-Il   Ahn Young-Keun   Hur Seung-Ho   Park Dae-Gyun   Choi Dong-Ju   Lee Seung-Uk   Kim Bum-Soo   Ryu Kyu-Hyung   Jang Yang-Soo   Lee Sang-Hoon   Seung Ki-Bae   Kim Hyo-Soo  

Publisher： Springer Publishing Company

ISSN： 0920-3206

Source： Cardiovascular Drugs and Therapy, Vol.24, Iss.2, 2010-04, pp. : 181-188

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of the Single-Dose Pharmacokinetics of Once-Daily Cyclobenzaprine Extended-Release 30 mg and Cyclobenzaprine Immediate-Release 10 mg Three Times Daily in the Elderly: A Randomized, Open-Label, Crossover Study

By Darwish Mona  

Drugs & Aging, Vol. 26, Iss. 2, 2009-01 ,pp. : 95-101

Adis International

Access to resources Recommend Favorite

Single-Dose Pharmacokinetics of Once-Daily Cyclobenzaprine Extended Release 30 mg versus Cyclobenzaprine Immediate Release 10 mg Three Times Daily in Healthy Young Adults: A Randomized, Open-Label, Two-Period Crossover, Single-Centre Study

By Darwish Mona   Hellriegel Edward T.   Xie Fang  

Clinical Drug Investigation, Vol. 28, Iss. 12, 2008-01 ,pp. : 793-801

Adis International

Access to resources Recommend Favorite

Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4 mg/day to Solifenacin Treatment: An Open-Label, Flexible-Dosing, Multicentre Study

By Swift Steven E.  

Clinical Drug Investigation, Vol. 29, Iss. 5, 2009-01 ,pp. : 305-316

Adis International

Access to resources Recommend Favorite

Effect of Food on the Pharmacokinetics of Once-Daily Cyclobenzaprine Extended-Release 30 mg: A Randomized, Open-Label, Crossover, Single-Centre Study

By Darwish Mona  

Clinical Drug Investigation, Vol. 29, Iss. 3, 2009-02 ,pp. : 145-152

Adis International

Access to resources Recommend Favorite

Blood Pressure-Lowering Efficacy of an Olmesartan Medoxomil/Hydrochlorothiazide-Based Treatment Algorithm in Elderly Patients (Age ≥65 Years) Stratified by Age, Sex and Race: Subgroup Analysis of a 12-Week, Open-Label, Single-Arm, Dose-Titration Study

By Neutel Joel  

Drugs & Aging, Vol. 28, Iss. 6, 2011-06 ,pp. : 477-490

Adis International

Access to resources Recommend Favorite